178 related articles for article (PubMed ID: 36778311)
1. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
bioRxiv; 2023 Feb; ():. PubMed ID: 36778311
[TBL] [Abstract][Full Text] [Related]
2. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2306782120. PubMed ID: 37607227
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Garris CS; Wong JL; Ravetch JV; Knorr DA
Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011627
[TBL] [Abstract][Full Text] [Related]
4. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
5. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Knorr DA; Dahan R; Ravetch JV
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11048-11053. PubMed ID: 30297432
[TBL] [Abstract][Full Text] [Related]
7. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
9. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
10. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
11. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
12. Agonistic CD40 Antibodies in Cancer Treatment.
Djureinovic D; Wang M; Kluger HM
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804039
[TBL] [Abstract][Full Text] [Related]
13. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
14. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
15. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.
Beckmann K; Reitinger C; Yan X; Carle A; Blümle E; Jurkschat N; Paulmann C; Prassl S; Kazandjian LV; Loré K; Nimmerjahn F; Fischer S
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651411
[TBL] [Abstract][Full Text] [Related]
16. CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner.
Leblond MM; Tillé L; Nassiri S; Gilfillan CB; Imbratta C; Schmittnaegel M; Ries CH; Speiser DE; Verdeil G
Cancer Immunol Res; 2020 Sep; 8(9):1180-1192. PubMed ID: 32661095
[TBL] [Abstract][Full Text] [Related]
17. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Weiss JM; Back TC; Scarzello AJ; Subleski JJ; Hall VL; Stauffer JK; Chen X; Micic D; Alderson K; Murphy WJ; Wiltrout RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19455-60. PubMed ID: 19892741
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
[TBL] [Abstract][Full Text] [Related]
19. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
20. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.
Van Audenaerde JR; Marcq E; von Scheidt B; Davey AS; Oliver AJ; De Waele J; Quatannens D; Van Loenhout J; Pauwels P; Roeyen G; Lardon F; Slaney CY; Peeters M; Kershaw MH; Darcy PK; Smits EL
Clin Transl Immunology; 2020; 9(8):e1165. PubMed ID: 32821382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
